These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7865347)

  • 1. Interleukin-1 and related pro-inflammatory cytokines in the treatment of bacterial infections in neutropenic and non-neutropenic animals.
    van der Meer JW; Vogels MT; Kullberg BJ
    Biotherapy; 1994; 7(3-4):161-7. PubMed ID: 7865347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proinflammatory cytokines and treatment of disease.
    VAN DER Meer JWM; Vogels MTE; Netea MG; Kullberg BJ
    Ann N Y Acad Sci; 1998 Sep; 856():243-251. PubMed ID: 9917883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-1 as a possible agent for treatment of infection.
    van der Meer JW; Vogels M; Curfs JH; Eling WM
    Eur J Clin Microbiol Infect Dis; 1993; 12 Suppl 1():S73-7. PubMed ID: 8477769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Indications for antimicrobial treatment in immunocompromised granulocytopenic patients].
    Ternák G; Almási I
    Orv Hetil; 1995 Aug; 136(32):1707-12. PubMed ID: 7651704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokines in the treatment of fungal infections.
    Kullberg BJ; van 't Wout JW
    Biotherapy; 1994; 7(3-4):195-210. PubMed ID: 7865351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to treat severe infections in critically ill neutropenic patients?
    Zafrani L; Azoulay E
    BMC Infect Dis; 2014 Nov; 14():512. PubMed ID: 25431154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunology in clinical practice. VIII. Role of cytokines in the pathogenesis of bacterial infections].
    van der Poll T; Speelman P; van Deventer SJ
    Ned Tijdschr Geneeskd; 1998 Jan; 142(1):14-7. PubMed ID: 9556983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do proinflammatory cytokine levels predict serious complication risk of infection in pediatric cancer patients?
    Karakurt DG; Demirsoy U; Corapcioglu F; Oncel S; Karadogan M; Arisoy ES
    Pediatr Hematol Oncol; 2014 Aug; 31(5):415-24. PubMed ID: 24499434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When to Use Prophylactic Antibiotics in Neutropenic Patients.
    Zimmer A; Freifeld A
    Oncology (Williston Park); 2016 Sep; 30(9):838-40, 846. PubMed ID: 27633416
    [No Abstract]   [Full Text] [Related]  

  • 10. Enhancement of antibacterial resistance of neutropenic, bone marrow-suppressed mice by interleukin-1 alpha.
    McIntyre KW; Unowsky J; DeLorenzo W; Benjamin W
    Infect Immun; 1989 Jan; 57(1):48-54. PubMed ID: 2783314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible roles for anti- or pro-inflammatory therapies in the management of sepsis.
    Silver GM; Fink MP
    Surg Clin North Am; 1994 Jun; 74(3):711-23. PubMed ID: 7515196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma endotoxin and cytokine levels in neutropenic and non-neutropenic bacteremic patients.
    Hynninen M; Valtonen M; Vaara M; Markkanen H; Kuusela P; Saxen H; Takkunen O
    Eur J Clin Microbiol Infect Dis; 1995 Dec; 14(12):1039-45. PubMed ID: 8681977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor.
    Kuritzkes DR
    Clin Infect Dis; 2000 Feb; 30(2):256-60. PubMed ID: 10671324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empiric therapy for infections in the febrile, neutropenic, compromised host.
    Giamarellou H
    Med Clin North Am; 1995 May; 79(3):559-80. PubMed ID: 7752729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of fungal and other opportunistic infections in immunocompromised patients.
    Wade JC
    Leukemia; 1997 May; 11 Suppl 4():S38-9. PubMed ID: 9179282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced antibacterial resistance in neutropenic mice treated with human recombinant interleukin-1 beta.
    Gladue R; Girard A; Newborg M
    Agents Actions; 1988 Jun; 24(1-2):130-6. PubMed ID: 3044030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of interleukin-8 on nonspecific resistance to infection in neutropenic and normal mice.
    Vogels MT; Lindley IJ; Curfs JH; Eling WM; van der Meer JW
    Antimicrob Agents Chemother; 1993 Feb; 37(2):276-80. PubMed ID: 8452358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential gene expression for IL-1 receptor antagonist, IL-1, and TNF receptors and IL-1 and TNF synthesis may explain IL-1-induced resistance to infection.
    Vogels MT; Mensink EJ; Ye K; Boerman OC; Verschueren CM; Dinarello CA; van der Meer JW
    J Immunol; 1994 Dec; 153(12):5772-80. PubMed ID: 7989774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Options for the treatment of serious infections with interleukin-1.
    van der Meer JW
    Biotherapy; 1989; 1(4):313-7. PubMed ID: 2701646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologicals and hematopoietic cytokines in prevention or treatment of infections in immunocompromised hosts.
    Roilides E; Pizzo PA
    Hematol Oncol Clin North Am; 1993 Aug; 7(4):841-64. PubMed ID: 7689074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.